T. Rowe Price Investment Management
BBOT

T. Rowe Price Investment Management’s BridgeBio Oncology BBOT Stock Holding History

T. Rowe Price Investment Management’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-397,962
Closed -$4.5M – 744
2025
Q1 		$4.5M Sell
397,962
-2,285
-0.6% -$24.6K ﹤0.01% 590
2024
Q4 		$4.2M Buy
400,247
+2,598
+0.7% +$27.3K ﹤0.01% 580
2024
Q3 		$4.16M Sell
397,649
-2,351
-0.6% -$24.3K ﹤0.01% 570
2024
Q2 		$4.09M Hold
400,000
– – ﹤0.01% 576
2024
Q1 		$4.14M Buy
+400,000
New +$4.14M ﹤0.01% 574

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HCI
Harraden Circle Investments New York $499M AUM 19.71% 1-Year Est. Return

T. Rowe Price Investment Management's BBOT Position: Q2 2025 in Review

T. Rowe Price Investment Management sold out of BridgeBio Oncology (BBOT) in Q2 2025, closing a stake of 397,962 shares — an estimated $4.5M sold.

T. Rowe Price Investment Management first reported a position in BBOT in Q1 2024 and held it in 5 quarters. The position peaked at $4.5M in Q1 2025. 34 funds tracked by Wall St. Rank hold BBOT as of Q2 2025.

  • T. Rowe Price Investment Management reported no remaining BridgeBio Oncology position as of Q2 2025 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 397,962 BridgeBio Oncology shares in Q2 2025, an estimated $4.5M.
  • T. Rowe Price Investment Management first reported a position in BridgeBio Oncology in Q1 2024 and held it in 5 quarters.
  • T. Rowe Price Investment Management's BridgeBio Oncology position peaked at $4.5M in Q1 2025.
  • 34 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2025.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2025, filed 14 Aug 2025.